Potential therapeutic role for statins in respiratory disease. - Wikidata - awgldk - TriplyDB

Potential therapeutic role for statins in respiratory disease.

Potential therapeutic role for statins in respiratory disease.

http://www.wikidata.org/entity/Q36551235

about

The stats are in: an update on statin use in COPD Emerging therapies for severe asthma Treatment of allergic asthma: modulation of Th2 cells and their responses Bronchiectasis in the Last Five Years: New Developments Effects of two Chinese herbal formulae for the treatment of moderate to severe stable chronic obstructive pulmonary disease: a multicenter, double-blind, randomized controlled trial Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease Controversial data on simvastatin in asthma: What about the rat model?Effects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial.Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation.Simvastatin for the prevention of exacerbations in moderate-to-severe COPD Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages.Dry powder formulation of simvastatin.Biological Effects of Simvastatin Formulated as pMDI on Pulmonary Epithelial Cells.Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma.Emerging roles for cholesterol and lipoproteins in lung disease.Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes.Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena.Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.Cardiovascular injury and repair in chronic obstructive pulmonary disease.Do statins protect against upper gastrointestinal bleeding?Methacoline Challenge test as an Evaluator of Response to Statins in Bronchial Hyperresponsiveness.Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis.[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.Targeting the airway smooth muscle for asthma treatment.Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond.The association of cardioprotective medications with pneumonia-related outcomes.Effect of simvastatin on MMPs and TIMPs in cigarette smoke-induced rat COPD model.Challenges of treating asthma in people who smoke.Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.Statins as emerging treatments for asthma and chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management.Emerging drugs for chronic obstructive pulmonary disease.A systematic review of statin efficacy in asthma.Newer glucocorticosteroids and corticosteroid resistance reversal in asthma.Novel approaches to the management of noneosinophilic asthma.Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons.Addressing corticosteroid insensitivity in adults with asthma.Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy.

P2860

Q26778906-6B4770CB-3A2B-486C-9882-861E672A573B Q26861260-2B70D650-46FA-44C8-B2E6-43B346E824F0 Q27011823-89B831BC-88DF-4403-A6E0-18D2F8429192 Q28075732-F83DA46E-3BB7-4C59-861B-03A924288942 Q28541874-4C81F905-AF41-4B67-8DD3-A0DD37CDA1D4 Q30492867-BA1B0904-08A8-42C3-B240-ECFE3B8FDA9F Q33855464-DB9D7B10-20FB-4B2F-9E15-703781331FF5 Q33865223-ACFC1977-3FCB-402F-87E7-9DFF14C1D47C Q34635121-E628FD39-6770-4221-BC08-CB78E1470FC7 Q34661935-98533AD2-D8F7-4CAE-AED4-7287FF2D0455 Q34989168-967D1D7F-D8B5-4037-B22D-5B76E162D1C6 Q35269057-78357748-13D9-4364-AC9F-511FDD952E6F Q35735440-0527393B-9516-4976-A68B-348ED5F49A23 Q35810049-FE502C1A-EDEE-4DF7-AF6F-99601443FC57 Q35999292-C9329CDF-A8F9-4FD6-A396-53C3372B9EB3 Q36252920-E6058983-10C8-4846-ACF1-4311A87D1237 Q36303634-8936A172-1D29-457B-846B-BAC6CE2BB2D6 Q36379603-643B1CE2-D1C5-4004-B038-8F003A6EA616 Q36742804-6C1CB50D-E500-4036-AE77-B5CA356837B4 Q36956720-F89C6953-0276-4648-AA2C-9ECB6376F97C Q37098445-4C360645-0F0F-41AF-BBFD-FFFD44A874BC Q37184446-227FA7ED-1C2F-4B9A-A09D-929DF7448358 Q37268223-B9BDF163-3E6C-421C-8559-92D9557200D8 Q37307795-290D5196-92E7-4C03-80C2-F2A1E181682D Q37343748-3EFE3FC6-051A-4078-A95B-0A03B1AADE24 Q37393160-E1BD43B4-D8E7-4ED6-B810-C0099515CE3F Q37423130-94A6F2D8-E3F9-4289-8F4E-CAF539287681 Q37525118-B18BF10D-4A93-4ABF-83C6-CBF7B702559E Q37669179-E29E9897-75A2-4BFF-85E5-330DED3C38BB Q37733518-E3E511E5-6910-49B2-8773-B3736E08DE7A Q37734257-3DEAA6B0-18D8-425B-ACFE-A04236EA1DA7 Q37754865-DC8EF985-629A-43F6-B297-D35CADFD0D96 Q37880077-9BEDECEE-7AE3-4613-AD4D-7A0A97B90814 Q37984088-63F937C8-6194-4BCF-A2F5-B8A2EC4571E9 Q38049185-6376A5E4-10C9-45EE-AEBC-7134191F444D Q38162976-0BAB73DF-4ADB-476F-B5AC-E178C838ACC8 Q38756064-CA660671-E5EC-433D-9648-A313DF0897C7 Q38841393-F9FE5650-B59B-499B-AEFF-FB141EAB78D7 Q38930984-5D2741E4-EF1D-4339-8933-E0DBB7843BCE Q39514476-45AFB2BF-A245-4C87-97A0-74DFC206C77B

P2860

Potential therapeutic role for statins in respiratory disease.

http://www.wikidata.org/entity/Q36551235

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Potential therapeutic role for statins in respiratory disease.

@ast

Potential therapeutic role for statins in respiratory disease.

@en

type

label

Potential therapeutic role for statins in respiratory disease.

@ast

Potential therapeutic role for statins in respiratory disease.

@en

prefLabel

Potential therapeutic role for statins in respiratory disease.

@ast

Potential therapeutic role for statins in respiratory disease.

@en

P1433

Q36551235-321323C9-09DF-446E-9D38-C1A8B8216B15

P1476

Q36551235-79252CBB-7B1E-4525-A5F7-B4E3CB23E5A2

P2093

Q36551235-73C048E4-9DDC-45C8-86A7-54E4B14037A4

Q36551235-9A91B140-D7EC-48A7-9005-7A2F4E286536

Q36551235-D9C6495F-9BD9-457F-813A-0E42B0E92A20

P2860

Q36551235-03F02559-CD89-45AB-AF71-37FDB64081C8

Q36551235-06B37642-B33F-44B6-A466-73D0A1431BDF

Q36551235-0E140D8C-3829-4FE6-8601-84E58F4C92B1

Q36551235-0F3C74CA-7B8E-4A5D-B7C0-562FCC8FBC08

Q36551235-1198B989-144E-424A-96AE-550FCC39D34B

Q36551235-133B5B98-81D4-4DD8-A4F6-C1FC922AA427

Q36551235-161E5B71-6206-4ABC-971B-EE50260EE87C

Q36551235-16F569F7-FB92-408B-8671-D7A752B9602D

Q36551235-179A4BC6-F324-4F53-9A5A-D00DF0A5B843

Q36551235-2165B3C1-A21D-43DD-999D-EABA18361DB1

P304

Q36551235-BF54B4FF-F089-44C4-AB88-BA17D8280AA2

P31

Q36551235-624A6A44-00B7-4C3C-B3DC-27EE2F16310A

P356

Q36551235-0E3B6AD3-673B-4804-A6AD-42AE4C7F557D

P407

Q36551235-D6774DA0-C3D4-45BF-96E7-0A15D8A4D50B

P433

Q36551235-12BA4515-CF52-4B6B-BCF7-7DC783BF02FB

P478

Q36551235-3CA4E732-0629-455C-84C6-5C43A1346221

P577

Q36551235-BE1139AC-A30C-4D73-9AB7-26AA68483105

P5875

Q36551235-14E82FCF-A7C6-430F-AF82-360C7BB2BF1E

P698

Q36551235-0CE915D4-B104-4FD7-8FDB-84D6C22E7E00

P932

Q36551235-E90D5821-4C4B-4797-8B28-91F5223B6B76

P356

THX.2005.057976

P1433

P1476

Potential therapeutic role for statins in respiratory disease.

@en

P2093

C McSharry

http://www.w3.org/2001/XMLSchema#string

E Hothersall

http://www.w3.org/2001/XMLSchema#string

N C Thomson

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

Cellular antioxidant effects of atorvastatin in vitro and in vivo.

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.

Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.

P304

729-734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.2005.057976

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6908322

http://www.w3.org/2001/XMLSchema#string

P698

16877692

http://www.w3.org/2001/XMLSchema#string

P932

2104700

http://www.w3.org/2001/XMLSchema#string